about icvs | People | MARIAVEIGA


Name: Maria Isabel Veiga

Office: I3.02

School Phone: +351 253 604 834

Email: mariaveiga@med.uminho.pt




Keywords: Malaria Drug resistance Drug development Diagnostic tools


Isabel Veiga, holds a degree in Biotechnology Engineering and a PhD in Medical Sciences taken at Karolinska Institute in 2011.She has postdoc experience at three different institutions (Karolinska Institute, Columbia University and University of Minho) and presently, at ICVS, leads a team supervising 2 PhD students and co-supervising 3,supported by national and international research grants.

Isabel Veiga research interests, endorsed for more than 16 years, focus on the malaria parasite factors that mediate resistance to antimalarial drugs and the parasite physiological changes and biological processes behind drug exposure, fostering on drug development (holds 1 European drug patent) and novel malaria diagnostic tools. 

In the context of the COVID-19 pandemic, Isabel Veiga is volunteer in the diagnostic service provided by UMinho to the community and with funding from “RESEARCH 4 COVID19" - special support for rapid implementation projects” promoted by the Foundation for Science and Technology (FCT), in collaboration with the Agency for Clinical Research and Biomedical Innovation (AICIB), is developing an innovative and differentiated molecular diagnostic method for SARS-CoV-2.

International impact of her research can be accessed by the over 1100 citations of 29 peer reviewed articles (CIF:168 and h-index:17).

In recognition of her work, she was awarded in 2016 by L'Oréal Portugal/UNESCO with an Honor Medal for Women in Science given by the president of Portugal, Dr. Marcelo Rebelo de Sousa. In2018, awarded by the Dominican Republic Ministry of Higher Education Science and Technology with an “Honorary Titular Researcher Category” for the endorsement to promote science in the country. In 2019, invited by the president of the Portuguese Agency for Scientific Culture and Technology - Ciência Viva, to endorse the 2nd edition of the book “Women in Science”.


PhD students:

Carla Calçada
Miguel Silva
Ana Rita Pedrosa
Leyre Pernaute
Vitoria Baptista



Calçada C, Silva M, Baptista V, Thathy V, Silva-Pedrosa R, Granja D, Ferreira PE, Gil JP, Fidock DA, Veiga MIExpansion of a Specific Plasmodium falciparum PfMDR1 Haplotype in Southeast Asia with Increased Substrate Transport. mBio. 2020 Dec 1;11(6):e02093-20. doi: 10.1128/mBio.02093-20.

Borges V, Isidro J, Cortes-Martins H, Duarte S, Vieira L, Leite R, Gordo I, Caetano CP, Nunes B, Sá R, Oliveira A, Guiomar R; Portuguese network for SARS-CoV-2 genomics, Gomes JP. Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal. Emerg Microbes Infect. 2020 Dec;9(1):2488-2496. doi: 10.1080/22221751.2020.1844552.

Sousa J, Cá B, Maceiras AR, Simões-Costa L, Fonseca KL, Fernandes AI, Ramos A, Carvalho T, Barros L, Magalhães C, Chiner-Oms Á, Machado H, Veiga MI, Singh A, Pereira R, Amorim A, Vieira J, Vieira CP, Bhatt A, Rodrigues F, Rodrigues PNS, Gagneux S, Castro AG, Guimarães JT, Bastos HN, Osório NS, Comas I, Saraiva M. Mycobacterium tuberculosis associated with severe tuberculosis evades cytosolic surveillance systems and modulates IL-1ß production. Nat Commun. 2020 Apr 23;11(1):1949. doi: 10.1038/s41467-020-15832-6.

Veiga MI, Peng WK. Rapid phenotyping towards personalized malaria medicine. Malar J. 2020 Feb 11;19(1):68. doi: 10.1186/s12936-020-3149-4.

Silva M, Calçada C, Teixeira M, Veiga MI, Ferreira PE. Multigenic architecture of piperaquine resistance trait in Plasmodium falciparum. Lancet Infect Dis. 2020 Jan;20(1):26-27. doi: 10.1016/S1473-3099(19)30689-9.

Catarino SO, Felix P, Sousa PJ, Pinto V, Veiga MI, Minas G. Portable Device for Optical Quantification of Hemozoin in Diluted Blood Samples. IEEE Trans Biomed Eng. 2020 Feb;67(2):365-371. doi: 10.1109/TBME.2019.2913454

Silva M, Ferreira PE, Otienoburu SD, Calçada C, Ngasala B, Björkman A, Mårtensson A, Gil JP, Veiga MI. Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy. J Antimicrob Chemother. 2019 Mar 14. pii: dkz098. doi: 10.1093/jac/dkz098. [Epub ahead of print]

Inoue J, Silva M, Fofana B, Sanogo K, Mårtensson A,Sagara I, Björkman A, Veiga MI,Ferreira PE, Djimde A, Gil JP. Plasmodium falciparum Plasmepsin 2 Duplications, West Africa. Emerg Infect Dis. 2018 Aug 17;24(8). doi: 10.3201/eid2408.180370

Cruz M, Sánchez IM, Diaz J, Cuevas F, Silva M, DislaM, Ferreira PE, Veiga MI. Dosage of Single Low-Dose Primaquine to Stop MalariaTransmission. J Infect Dis. 2018 May5;217(11):1849-1850. doi: 10.1093/infdis/jiy108.

Vanaerschot M, Lucantoni L, Li T, Combrinck JM,Ruecker A, Kumar TRS, Rubiano K, Ferreira PE, Siciliano G, Gulati S, HenrichPP, Ng CL, Murithi JM, Corey VC, Duffy S, Lieberman OJ, Veiga MI, Sinden RE, Alano P, Delves MJ, Lee Sim K, Winzeler EA,Egan TJ, Hoffman SL, Avery VM, Fidock DA. Hexahydroquinolines are antimalarialcandidates with potent blood-stage and transmission-blocking activity. Nat Microbiol. 2017 Aug 14. doi:10.1038/s41564-017-0007-4.

Veiga MI,Dhingra, S.K.,Henrich, P.P., Straimer, J., Gnadig, N., Uhlemann, AC., Martin, R.E., Lehane,A.M., Fidock, D.A.. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility toartemisinin-based combination therapies. NatureCommunications; 2016 May 18;7:11553.

Veiga MI, Osório NS, FerreiraPE, Franzén O, Dahlstrom S, Lum JK, Nosten F, Gil JP. Complex polymorphisms in the Plasmodium falciparumMultidrug Resistance Protein 2 gene and its contribution to antimalarialresponse. Antimicrob Agents Chemother. 2014Dec;58(12):7390-7. 


Defining redox pathways in antimalarial drug resistance (Leader) 

Detoxification mechanisms in Plasmodium falciparum malaria (Leader) 

Genetic determinants of malaria resistance in Dominican Republic (Leader) 

Importance of Plasmodium falciparum ABC transporters in antimalarial drug resistance (Leader) 

Computational Molecular Biology and Evolution of the Mycobacterium tuberculosis Complex  

Functional impact of allelic variants of metabolic genes under positive selection in the fitness of Mycobacterium tuberculosis  

Selected Publications

Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnadig N, Uhlemann AC, Martin RE, Lehane AM, Fidock DA. "Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies". Nat Commun. 2016 May 18;7:11553.

Veiga MI, Ferreira PE, Malmberg M, Jörnhagen L, Björkman A, Nosten F, Gil JP. pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine. Antimicrob Agents Chemother. 2012 Jul;56(7):3615-9. doi: 10.1128/AAC.06350-11. Epub 2012 Apr 16.

Vanaerschot M, Lucantoni L, Li T, Combrinck J, Ruecker A, Kumar TR, Rubiano K, Ferreira PE, Siciliano G, Gulati S, Henrich P, Ng C, Murithi J, Corey V, Duffy S, Lieberman O, Veiga MI, Sinden R, Alano P, Delves M, Sim KL, Winzeler E, Egan T, Hoffman SL, Avery V, Fidock D. "Hexahydroquinolines are Antimalarial Candidates with Potent Blood Stage and Transmission-Blocking Activity". Nat Microbiol. 2017 Oct;2(10):1403-1414.

Veiga MI, Osório NS, Ferreira PE, Franzén O, Dahlstrom S, Lum JK, Nosten F, Gil JP. Complex polymorphisms in the Plasmodium falciparum Multidrug Resistance Protein 2 gene and its contribution to antimalarial response. Antimicrob Agents Chemother. 2014 Sep 29. pii: AAC.03337-14. [Epub ahead of print]

Jovel IT, Ferreira PE, Veiga MI, Malmberg M, Mårtensson A, Kaneko A, Zakeri S, Murillo C, Nosten F, Björkman A, Ursing J. Single nucleotide polymorphisms in Plasmodium falciparum V type H+ pyrophosphatase gene (pfvp2) and their associations with pfcrt and pfmdr1 polymorphisms. Infect Genet Evol. 2014 Mar 20;24C:111-115. doi: 10.1016/j.meegid.2014.03.004

Copyright © 2012-2016 ICVS. All rights reserved.